{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:58:34Z","timestamp":1791176314550,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tampere University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Despite clear clinical guidelines advising against the use of cough and cold medicines (CCMs) in children, these products continue to be prescribed. We aimed at describing recent trends and identifying deviations from guidelines to inform future targeted interventions. We retrospectively retrieved data on all CCM prescriptions for children under 16\u00a0years of age in Finland between 2017 and 2023 from the centralised nationwide prescription registry. Descriptive statistical methods were used to analyse the data, stratified by child\u2019s age, CCM type, physician\u2019s employment sector, and medical specialty. The dataset included 96,499 prescriptions for 75,281 children. Overall, CCM prescribing decreased significantly from 2017 to 2023, particularly between 2017 and 2020, with the steepest decline in the 2\u20134.99-year age group. Prescribing levels did not return to pre-pandemic levels in any age group. Opium alkaloids and their derivatives were the most commonly prescribed CCMs for children under the age of 12. CCM prescribing rates were nearly identical across public and private sectors. Approximately 40% of prescriptions were issued by non-specialists and 18% by medical students\u2014who constituted the largest group of public sector prescribers. In the private sector, the most frequent prescribers were paediatricians, non-specialists, general medicine specialists, and otolaryngologists. <jats:italic>Conclusions<\/jats:italic>: CCMs and especially opium alkaloids and their derivatives are still being prescribed even to small children. These findings should prompt nationwide multifaceted clinical guidance campaigns and interventions targeting medical students and non-specialist physicians, as well as private sector providers, including paediatricians and other specialists.\n<jats:table-wrap>\n              <jats:table>\n                <jats:tbody>\n                  <jats:tr>\n                    <jats:td colspan=\"2\">\n                      <jats:bold>What is known:<\/jats:bold>\u2022 <jats:italic>Despite guidelines advising against cough and cold medicines (CCMs) in children, prescribing persists<\/jats:italic>.<\/jats:td>\n                  <\/jats:tr>\n                  <jats:tr>\n                    <jats:td colspan=\"2\">\n                      <jats:bold>What is new:<\/jats:bold>\u2022 <jats:italic>CCM prescriptions for children declined markedly in Finland between 2017\u20132023, however opium alkaloids remained the most common among children under 12, despite CNS safety concerns. Non-specialists, general practitioners, and medical students prescribed CCMs most frequently. Specialist physicians were more likely to prescribe CCMs in the private sector, while the public sector had a broader mix of prescribers<\/jats:italic>.<\/jats:td>\n                  <\/jats:tr>\n                <\/jats:tbody>\n              <\/jats:table>\n            <\/jats:table-wrap>\n          <\/jats:p>","DOI":"10.1007\/s00431-025-06306-2","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:07:58Z","timestamp":1751915278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cough medicine prescriptions for children by physician specialty and healthcare sector: a Finnish population-based nationwide register study"],"prefix":"10.1007","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0819-7875","authenticated-orcid":false,"given":"P\u00e9ter","family":"Csonka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-0173","authenticated-orcid":false,"given":"Fredriikka","family":"Nurminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4654-7602","authenticated-orcid":false,"given":"Eero","family":"Lauhkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-2552","authenticated-orcid":false,"given":"Heini","family":"Kari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"6306_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1471-2296-14-106","volume":"14","author":"J Ingram","year":"2013","unstructured":"Ingram J, Cabral C, Hay AD, Lucas PJ, Horwood J (2013) Parents\u2019 information needs, self-efficacy and influences on consulting for childhood respiratory tract infections: a qualitative study. BMC Fam Pract 14:106","journal-title":"BMC Fam Pract"},{"key":"6306_CR2","doi-asserted-by":"crossref","unstructured":"Hay AD, Heron J, Ness A (2005) ALSPAC study team. The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study. Fam Pract 22:367\u201374","DOI":"10.1093\/fampra\/cmi035"},{"key":"6306_CR3","doi-asserted-by":"crossref","unstructured":"Smith S, Schroeder K, Fahey T (2014) Over-the-counter (OTC) medications for acute cough in children and adults in community settings. Cochrane Database Syst Rev 24;2014(11):CD001831","DOI":"10.1002\/14651858.CD001831.pub5"},{"key":"6306_CR4","doi-asserted-by":"crossref","unstructured":"Gardiner S, Chang A, Marchant J, Petsky H (2016) Codeine versus placebo for chronic cough in children ( Review ). Cochrane Database Of Systematic Rev 13;7(7):CD011914","DOI":"10.1002\/14651858.CD011914.pub2"},{"key":"6306_CR5","unstructured":"American Academy of Pediatrics (2014) Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. [Internet]. Available from: https:\/\/www.aapdc.org\/wp-content\/uploads\/2014\/03\/AAP-Choose-Wisely-Top-10-Updated-Mar-2014.pdf.\u00a0Accessed 7 Apr\u00a02025"},{"key":"6306_CR6","unstructured":"U.S. Food and Drug Administration (2018) Use caution when giving cough and cold products to kids. [Internet]. Available from: https:\/\/www.fda.gov\/drugs\/special-features\/use-caution-when-giving-cough-and-cold-products-kids.\u00a0Accessed 7 Apr\u00a02025"},{"key":"6306_CR7","unstructured":"Health Canada  (2008) Health Canada Releases Decision on the Labelling of Cough and Cold Products for Children [Internet]. Available from: https:\/\/www.healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2008\/13267a-eng.php.\u00a0Accessed 7 Apr 2025"},{"key":"6306_CR8","unstructured":"U.S. Food and Drug Administration (2008) FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older [Internet]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-requires-labeling-changes-prescription-opioid-cough-and-cold.\u00a0Accessed 7 Apr\u00a02025"},{"key":"6306_CR9","unstructured":"European Medicines Agency (2015) Codeine-containing medicinal products for the treatment of cough or cold in paediatric patients [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/codeine-containing-medicinal-products-treatment-cough-cold-paediatric-patients#overview-section.\u00a0Accessed 7 Apr\u00a02025"},{"key":"6306_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1542\/peds.2013-2236","volume":"132","author":"LM Hampton","year":"2013","unstructured":"Hampton LM, Nguyen DB, Edwards JR, Budnitz DS (2013) Cough and cold medication adverse events after market withdrawal and labeling revision. Pediatrics 132:1047\u20131054","journal-title":"Pediatrics"},{"key":"6306_CR11","first-page":"30","volume":"48","author":"G Clark","year":"2023","unstructured":"Clark G, Fitzgerald DA, Rubin BK (2023) Cough medicines for children- time for a reality check. Paediatr Respir Rev 48:30\u201338x","journal-title":"Paediatr Respir Rev"},{"key":"6306_CR12","doi-asserted-by":"crossref","unstructured":"Tobias JD, Green TP, Cot\u00e9 CJ (2016) Section on anesthesiology and pain medicine, Committee on drugs, Agarwal R et al. Codeine: Time to Say \u201cNo.\u201d Pediatrics 138:e20162396","DOI":"10.1542\/peds.2016-2396"},{"key":"6306_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/ijpp\/riae045","volume":"32","author":"JB Shammah","year":"2024","unstructured":"Shammah JB, Scott J, Wazaify M (2024) Prescription and nonprescription drug misuse and abuse in community pharmacies in Iraq: a cross-sectional survey. Int J Pharm Pract 32:461\u2013469x","journal-title":"Int J Pharm Pract"},{"key":"6306_CR14","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1038\/s41598-024-55758-3","volume":"14","author":"O Sheehy","year":"2024","unstructured":"Sheehy O, Eltonsy S, Hawken S, Walker M, Kaul P, Winquist B et al (2024) Health Canada advisory impacts on the prevalence of oral codeine use in the Pediatric Canadian population: comparative study across provinces. Sci Rep 14:5370","journal-title":"Sci Rep"},{"key":"6306_CR15","unstructured":"The Finnish Medical Society Duodecim and the FPS and the FS of GMedicineHTFMS (2014) Lower respiratory tract infections (children). Current Care Guidelines [Internet]. Duodecim. Available from: www.kaypahoito.fi.\u00a0Accessed 26 Mar\u00a02025"},{"key":"6306_CR16","doi-asserted-by":"crossref","unstructured":"Kivist\u00f6 JE, Poutanen R, Protudjer JLP, Csonka P, Korppi M, Renko M, Palmu S (2021) Current care guidelines had no immediate effects on antitussive prescriptions to Finnish children. Acta Paediatr 110(8):2445\u20132447","DOI":"10.1111\/apa.15829"},{"key":"6306_CR17","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1542\/peds.2013-3171","volume":"133","author":"SV Kaiser","year":"2014","unstructured":"Kaiser SV, Asteria-Penaloza R, Vittinghoff E, Rosenbluth G, Cabana MD, Bardach NS (2014) National patterns of codeine prescriptions for children in the emergency department. Pediatrics 133:e1139\u2013e1147","journal-title":"Pediatrics"},{"key":"6306_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jamapediatrics.2019.2252","volume":"173","author":"DB Horton","year":"2019","unstructured":"Horton DB, Gerhard T, Strom BL (2019) Trends in cough and cold medicine recommendations for children in the United States, 2002\u20132015. JAMA Pediatr 173:885","journal-title":"JAMA Pediatr"},{"key":"6306_CR19","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jpeds.2014.07.047","volume":"165","author":"M Mazer-Amirshahi","year":"2014","unstructured":"Mazer-Amirshahi M, Rasooly I, Brooks G, Pines J, May L, van den Anker J (2014) The impact of pediatric labeling changes on prescribing patterns of cough and cold medications. J Pediatr 165:1024-1028.e1","journal-title":"J Pediatr"},{"key":"6306_CR20","doi-asserted-by":"publisher","unstructured":"Csonka P, Heikkil\u00e4 P, Koskela S, Palmu S, Lajunen N, Riihij\u00e4rvi S et al (2021) Cough and cold medicine prescription rates can be significantly reduced by active intervention. Eur J Pediatr. Available from: https:\/\/doi.org\/10.1007\/s00431-021-04344-0","DOI":"10.1007\/s00431-021-04344-0"},{"key":"6306_CR21","doi-asserted-by":"publisher","unstructured":"Palmu S, Heikkil\u00e4 P, Kivist\u00f6 JE, Poutanen R, Korppi M, Renko M et al (2022) Cough medicine prescriptions for children were significantly reduced by a systematic intervention that reinforced national recommendations. Acta Paediatr. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/apa.16284","DOI":"10.1111\/apa.16284"},{"key":"6306_CR22","unstructured":"Kanta (2024) Prescriptions and medicines [Internet]. Available from: https:\/\/www.kanta.fi\/en\/prescriptions-and-medicines.\u00a0Accessed 10 Apr\u00a02025"},{"key":"6306_CR23","doi-asserted-by":"publisher","first-page":"E423","DOI":"10.1097\/INF.0000000000002845","volume":"39","author":"I Kuitunen","year":"2020","unstructured":"Kuitunen I, Artama M, M\u00e4kel\u00e4 L, Backman K, Heiskanen-Kosma T, Renko M (2020) Effect of social distancing due to the COVID-19 pandemic on the incidence of viral respiratory tract infections in children in Finland during early 2020. Pediatr Infect J 39:E423\u2013E427","journal-title":"Pediatr Infect J"},{"key":"6306_CR24","unstructured":"Cocillana (2019) 1,25 mg\/ml oraalineste: K\u00e4ytt\u00f6 alle 12-vuotiailla uusi vasta-aihe [Internet]. Orion Pharma. Available from: https:\/\/fimea.fi\/documents\/147152901\/159465445\/Cocillana+DHPC+Final-FI+2019-10-25.pdf\/daaa86ff-cd6f-c8e7-fff4-05bd8cdd25ca\/Cocillana+DHPC+Final-FI+2019-10-25.pdf?t=1572005785918"},{"key":"6306_CR25","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1542\/peds.2010-1839","volume":"126","author":"N Shehab","year":"2010","unstructured":"Shehab N, Schaefer MK, Kegler SR, Budnitz DS (2010) Adverse events from cough and cold medications after a market withdrawal of products labeled for infants. Pediatrics 126:1100\u20131107","journal-title":"Pediatrics"},{"key":"6306_CR26","doi-asserted-by":"crossref","unstructured":"Sen EF, Verhamme KMC, Felisi M, \u2019t Jong GW, Giaquinto C, Picelli G et al (2011) Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age. Br J Clin Pharmacol 71:943\u201350","DOI":"10.1111\/j.1365-2125.2010.03860.x"},{"key":"6306_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/pds.5377","volume":"31","author":"R Masarwa","year":"2022","unstructured":"Masarwa R, Lefebvre C, Platt RW, Filion KB (2022) General practitioner prescribing trends among pediatric patients in the United Kingdom: 1998\u20132018. Pharmacoepidemiol Drug Saf 31:302\u2013313x","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6306_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5152\/eajm.2013.20","volume":"45","author":"S Mollahaliloglu","year":"2013","unstructured":"Mollahaliloglu S, Alkan A, Donertas B, Ozgulcu S, Akici A (2013) Prescribing practices of physicians at different health care institutions. Eurasian J Med 45:92\u201398","journal-title":"Eurasian J Med"},{"key":"6306_CR29","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1007\/s00431-023-05099-6","volume":"182","author":"R Poutanen","year":"2023","unstructured":"Poutanen R, Korppi M, Csonka P, Pauniaho SL, Renko M, Palmu S (2023) Use of antibiotics contrary to guidelines for children\u2019s lower respiratory tract infections in different health care settings. Eur J Pediatr 182:4369\u20134377","journal-title":"Eur J Pediatr"},{"key":"6306_CR30","unstructured":"Finnish Medicines Agency (Fimea) (2025) Finnish statistics on medicines. Available from: www.fimea.fi.\u00a0Accessed 16 June\u00a02025"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06306-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06306-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06306-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:44:12Z","timestamp":1758008652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06306-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["6306"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06306-2","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"471"}}